degrees C) when compared with our other patients at the time of apnoea testing.

J M BELSH*
PL SCHIFFMAN†
Departments of Neurology* and Medicine†,
Robert Wood Johnson Medical School,
1 Robert Wood Johnson Place, CN19
New Brunswick,
NJ 08903-0019 USA

References
7 Belsh JM, Schiffman PL, Blatt R. Apnoea testing for the determination of death by neurologic criteria (Brain Death). New Jersey Medicine 1986;83:593.

van Donselaar et al reply:

We completely agree with the comments made by Belsh and Schiffman. In the discussion-section of our paper we stated that the low pCO2 levels at the onset of the apnoea test might explain the insufficient levels after 10 minutes of apnoea. We also agree with their recommendation to adjust the minute volume prior to disconnection if the pCO2 is rather low. In a recent article for the journal of the Dutch Medical Association,1 we advised the following:

(1) if the pCO2 < 5.0 kPa (38 mmHg)
—preventilate with 100% O2 for 10 minutes
—disconnect the patient for 14 minutes while giving O2 via an endotracheal tube at a rate of 6 litres/min
—after drawing blood for blood gas determination re-connect the ventilator.
(2) if the pCO2 < 5.0 kPa (38 mmHg)
—preventilate with 100% O2 for 5 minutes
—continue ventilating with 100% O2 with a halved volume for 15 minutes
—disconnect the patient for 14 minutes while giving O2 via an endotracheal tube at a rate of 6 litres/min
—after drawing blood for blood gas determination re-connect the ventilator.

With this method, the pCO2 will have risen to 7-98 kPa or higher in most patients, while adequate oxygenation is secured.2,3 The test must be terminated in case of ventricular arrhythmias of hypotension. In our opinion blood gas determination at the end of the apnoea test is mandatory to see whether the pCO2 has reached the target value providing supramaximal stimulation of the respiratory centre. For patients with chronic lung disease we refer to the article of Rohling.4

References

Sino-atrial block provoked by carbamazepine

SIR: Stone and Lange1 have reported in your Journal the occurrence of ventricular asystole followed by syncope and death in a patient treated with carbamazepine for temporal lobe seizures. They also mention the occurrence of sinus bradycardia due to carbamazepine.

The following case confirms that carbamazepine may cause sino-atrial block. A 54 year old female suffering since the age of 32 from complex-partial seizures with automatisms with a frequency of about 3-5 per day, had been taking carbamazepine 1200 mg/day for one year with a plasma concentration of 6-3-9-0 µg/ml. The epileptic nature of seizures was documented by simultaneous ambulatory EEG and ECG monitoring; there were no secondary cardiac arrhythmias during the epileptic attack. She was hospitalised after falling from a small ladder without loss of consciousness while housekeeping. On admission, heart rate was 36 per minute and ECG showed rare, isolated monomorphic ventricular ectopic beats. Carbamazepine was discontinued. Pulse rate remained around 40 for a few hours and went back to normal the day after. During the following months the patient was unsuccessfully treated with phenoxytoin, clonazepam and phenobarbital in combination.

Carbamazepine treatment was resumed after the initial dosage of 150 mg, gradually increased to 300 and then 600 mg over an 4-month period, under weekly ECG controls. There was a considerable decrease in seizures. The patient had been taking 600 mg for 15 days when ECG evidenced a 2:1 sino-atrial block. Plasma concentration was not obtained. Discontinuation of the drug resulted in the disappearance of the arrhythmia in 24 hours. Follow-up examinations on the 3rd, 7th and 14th day did not show any conduction disorder.

Stone and Lange collected nine cases of conduction disorder due to carbamazepine. We may add the present case and a case of sino-atrial block reported by Meyrignac et al2 Given the wide application of this drug, the risk of cardiac complications seems likely and carbamazepine remains an excellent antiepileptic medication.

Blumhardt et al3 have demonstrated that simultaneous EEG and ECG monitoring that temporal lobe seizures are associated with increased heart rate in 24 out of 26 patients. In a series of 16 partial complex-epileptic patients monitored in our laboratory4 we have observed ictal tachycardia in 13; in two patients there was ictal bradycardia, starting 6-8 seconds from the beginning of the attack and attaining 15% and 53% of the basal frequency. Blumhardt et al3 actually suggest that antiepileptic medication may protect against the risk of sudden death in epileptic patients. The relationship between epilepsy, drugs and the heart must be therefore evaluated in the single patient. However, the need for cardiologic examination during carbamazepine prescription, emphasised by Stone and Lange, cannot be overestimated. The use of the drug should be cautious in patients with sick sinus syndrome or blocks at any level. Special attention must be given to elderly patients, who more frequently suffer from these diseases.

MARIO CURIONE
CESARE IANI